|Bid||131.75 x 1000|
|Ask||135.00 x 1100|
|Day's Range||128.57 - 138.36|
|52 Week Range||120.00 - 426.56|
|Beta (5Y Monthly)||0.85|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 08, 2018 - Aug 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||349.32|
Subscribe to Yahoo Finance Plus to view Fair Value for BGNE
CAMBRIDGE, Mass. & BASEL, Switzerland & BEIJING, May 17, 2022--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, yesterday announced the opening of a new regional office in Basel, Switzerland. BeiGene has built a European organization, including commercial and clinical teams, and this new location will serve as a hub for the company’s operations in the region.
CAMBRIDGE, Mass., BEIJING & BASEL, Switzerland, May 12, 2022--BeiGene announced 20 presentations from the Company’s global clinical development programs in hematologic malignancies at EHA.
A Roche failure in lung cancer sent a ripple through biotech stocks on Wednesday, toppling Arcus, BeiGene, Iteos and others.